EBS Emergent Biosolutions Inc.

38.34
+0.67  (2%)
Previous Close 37.67
Open 37.65
Price To book 2.55
Market Cap 1580051479
Shares 41,211,567
Volume 150,024
Short Ratio 7.75
Av. Daily Volume 300,279

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 171029813
  2. CT ORDER - Confidential treatment order 171029496
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171006272
  4. 8-K - Current report 171005447
  5. 8-K - Current report 17980670

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved May 17, 2012.
BioThrax
Anthrax Vaccine
Phase 1/2 ongoing
IONIS-DMPK-2.5Rx
Myotonic Dystrophy Type 1 (DM1)
Approved November 24, 2015.
BioThrax
Anthrax Vaccine Adsorbed
Approved March 25, 2015.
Anthrax Immune Globulin Intravenous (Human) [AIGIV]
Anthrax
Phase 2 data released November 2016.
IONIS-FXIRx
End-stage renal disease

SEC Filings

  1. CT ORDER - Confidential treatment order 171029813
  2. CT ORDER - Confidential treatment order 171029496
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171006272
  4. 8-K - Current report 171005447
  5. 8-K - Current report 17980670
  6. 8-K - Current report 17964520
  7. 8-K - Current report 17870276
  8. CT ORDER - Confidential treatment order 17841724
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 17815553
  10. 8-K - Current report 17814272